Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;42(3):469-81.
doi: 10.1016/j.clp.2015.04.004. Epub 2015 May 14.

Erythropoietin and Neonatal Neuroprotection

Sandra E Juul  1 , Gillian C Pet  2
Affiliations
Review

Erythropoietin and Neonatal Neuroprotection

Sandra E Juul et al. Clin Perinatol. 2015 Sep.

Abstract

Certain groups of neonates are at high risk of developing long-term neurodevelopmental impairment and might be considered candidates for neuroprotective interventions. This article explores some of these high-risk groups, relevant mechanisms of brain injury, and specific mechanisms of cellular injury and death. The potential of erythropoietin (Epo) to act as a neuroprotective agent for neonatal brain injury is discussed. Clinical trials of Epo neuroprotection in preterm and term infants are updated.

Keywords: Apoptosis; Autophagy; Brain injury; Erythropoietin; Extreme prematurity; Hypoxic ischemic encephalopathy; Necrosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hypoxic Ischemic Brain Injury
Figure 2
Figure 2
Neuroprotective Effects of Epo: Cell and tissue Repair
See this image and copyright information in PMC

References

    1. Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009;124(2):e218–26. Epub 2009/08/05. doi: peds.2008-3553 [pii] 10.1542/peds.2008-3553. PubMed PMID: 19651565. - PubMed
    1. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008;122(2):383–91. PubMed PMID: 18676557. - PubMed
    1. Fauchere JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008;122(2):375–82. Epub 2008/08/05. doi: 122/2/375 [pii] 10.1542/peds.2007-2591. PubMed PMID: 18676556. - PubMed
    1. Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012;130(4):683–91. Epub 2012/09/26. doi: 10.1542/peds.2012-0498. PubMed PMID: 23008465; PubMed Central PMCID: PMC3457622. - PMC - PubMed
    1. Rogers EE, Bonifacio SL, Glass HC, Juul SE, Chang T, Mayock DE, et al. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatr Neurol. 2014;51(5):657–62. doi: 10.1016/j.pediatrneurol.2014.08.010. PubMed PMID: 25439577. - PMC - PubMed